Focused On-demand Library for Tumor necrosis factor receptor superfamily member 13C

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96RJ3

UPID:

TR13C_HUMAN

Alternative names:

B-cell-activating factor receptor; BAFF receptor; BLyS receptor 3

Alternative UPACC:

Q96RJ3

Background:

Tumor necrosis factor receptor superfamily member 13C, also known as the B-cell-activating factor receptor (BAFF receptor), plays a pivotal role in B-cell survival and response. It specifically binds to TNFSF13B/BAFF, promoting mature B-cell survival and enhancing the B-cell response. This receptor is crucial for B-cell differentiation and immunoglobulin secretion.

Therapeutic significance:

The protein is directly linked to Immunodeficiency, common variable, 4, a disease characterized by antibody deficiency and recurrent bacterial infections due to impaired B-cell differentiation. Understanding the role of Tumor necrosis factor receptor superfamily member 13C could open doors to potential therapeutic strategies for treating immunodeficiency disorders.